Investment Analysts’ Weekly Ratings Updates for Adverum Biotechnologies (ADVM)

A number of firms have modified their ratings and price targets on shares of Adverum Biotechnologies (NASDAQ: ADVM) recently:

• 10/29/2025 – Adverum Biotechnologies was given a new $5.50 price target on by analysts at Mizuho.
• 10/28/2025 – Adverum Biotechnologies was given a new $4.00 price target on by analysts at Royal Bank Of Canada.
• 10/28/2025 – Adverum Biotechnologies had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $4.00 price target on the stock, up previously from $3.00.
• 10/27/2025 – Adverum Biotechnologies was downgraded by analysts at Chardan Capital from a “strong-buy” rating to a “hold” rating.
• 10/24/2025 – Adverum Biotechnologies was given a new $5.00 price target on by analysts at Truist Financial Corporation.
• 10/24/2025 – Adverum Biotechnologies was downgraded by analysts at Truist Financial Corporation from a “strong-buy” rating to a “hold” rating.
• 10/9/2025 – Adverum Biotechnologies was upgraded by analysts at Royal Bank Of Canada to a “hold” rating.
• 10/8/2025 – Adverum Biotechnologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Adverum Biotechnologies had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/23/2025 – Adverum Biotechnologies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.